Recombinant alpha 2B interferon (IFN) in the treatment of chronic hepatitis C disease in thalassaemia major (TM).

@article{Wonke1993RecombinantA2,
  title={Recombinant alpha 2B interferon (IFN) in the treatment of chronic hepatitis C disease in thalassaemia major (TM).},
  author={Beatrix Wonke and S M Donohue and Allan Victor Hoffbrand and Peter J. Scheuer and Dave Brown and Geoffrey Dusheiko},
  journal={Bone marrow transplantation},
  year={1993},
  volume={12 Suppl 1},
  pages={24-5}
}
Hepatitis C virus (HCV) is responsible for the majority of cases of post transfusion non-A non-B (NANB) hepatitis in thalassaemia major (TM). Fifteen multi-transfused TM patients with serological, biochemical, histological and molecular biological evidence of HCV infection have been treated for six months with recombinant alpha interferon (IFN). Eleven (73%) responded, 8 (53%) had complete response (CR), 3 (20%) partial response (PR) and 4 (27%) did not respond (NR) to IFN. Natural killer (NK… CONTINUE READING